Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Molgramostim is in phase 3 clinical trials to treat autoimmune pulmonary alveolar proteinosis, or aPAP. Molgramostim has received an FDA orphan drug designation — given to drugs targeting rare ...

for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The trial demonstrated statistically significant ...

In addition to the poster presentation, Savara Inc. is sponsoring an Industry Symposium titled “Pulmonary Alveolar ...

Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was ...

Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

ARP Atlases. 2007;1:17-47. The total number of leukocytes recovered by lavage is determined by examination of a sample of the pooled fluid with a hemocytometer. The cell counts are most accurate ...